X
X
Leaving Community
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
No
Yes
X
Blog
dkNET community events and announcements in October, 2022
Dear dkNET Community,
dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.
dkNET News
- dkNET Upcoming Webinar: Come join us for a webinar presented by Drs. Katy Börner and Jeffrey Spraggins on Friday, October 14, 2022 at 11 am - 12 pm PDT to learn about the Human BioMolecular Atlas Program (HuBMAP), an open and global framework for comprehensively mapping the human body at cellular resolution! Register it now: https://dknet.org/about/blog/2495
- dkNET team at HIRN 2022 Annual Investigator Meeting: Thank you to all who stopped by our poster and demos at HIRN Annual Meeting in Washington DC from September 14- 16, 2022. We were so excited to meet all these great investigators, scientists, and trainees studying Type 1 Diabetes in person! For those who were unable to see the dkNET demos, here is a list of short videos to show how to use different services/tools at dkNET: https://www.youtube.com/playlist?list=PLK-MmsEkavgifJX6T4Bra7hYIAFDAIoJz
- New resource and tutorial added to the dkNET Hypothesis Center: We have added MARRVEL(Model organism Aggregated Resources for Rare Variant ExpLoration) to the Hypothesis Center. Check out the MARRVEL tutorial and resource information to learn how to use MARRVEL and combine it with other publicly available online tools to generate the hypotheses, e.g., tutorial on using MMPC (Mouse Metabolic Phenotyping Centers) and MARRVEL to find pathogenic evidence in human diseases for mouse genes.
- New Resources added to dkNET
- MicrobiomeDB (RRID:SCR_022766) is a systems biology platform for integrating, mining, and analyzing microbiome experiments. It is a data discovery and analysis web-based resource that empowers researchers to fully leverage experimental variables to interrogate microbiome datasets. It is used to mine complex microbiome and metagenome studies.
- CellRank (RRID:SCR_022827) is a software package for directed single-cell fate mapping in diverse scenarios, including regeneration, reprogramming, and disease. It automatically detects initial, intermediate, and terminal populations, predicts fate potentials, and visualizes continuous gene expression trends along individual lineages. It is applied to lineage traced cellular reprogramming data, predicted fate probabilities correctly recover reprogramming outcomes
- GeneSwitches (RRID:SCR_022826) is a software tool to discover the order of gene expression and functional events during cell state transitions at single-cell resolution. It works on any single cell trajectory or pseudo time ordering of cells to discover genes that act as on/off switches between cell states and ordering at which these switches take place. It takes any single-cell pseudo-time trajectory and determines the precise order of gene expression and functional event changes over time.
- Harvard Tissue Atlas (RRID:SCR_022829) gathers together imaging and omic datasets into molecular maps of normal and diseased tissue from human and animal models, with emphasis on cancer. It is used to access datasets, educational curriculum and talks, and recommended methods and software.
- CytoTRACE (RRID:SCR_022828) is a software tool that predicts the differentiation state of cells from single-cell RNA sequencing data. It is used for predicting differentiation states from scRNA-seq data.
Events in October 2022
Oct. 01, 2022
D-Challenge Registration Deadline
Registration Deadline: October 1, 2022
Oct. 10, 2022
NIDDK Workshop Registration Due: Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies
Urologic Chronic Pelvic Pain Syndrome (UCPPS) represents both Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). The Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies meeting will provide a forum for exchange of new insights into UCPPS underlying mechanisms and clinical characteristics. The meeting will highlight findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network and other investigators working in the UCPPS field, as well as advances in other areas that may inform these efforts. Major themes will include strategies for identification of phenotypic sub-groups, mechanistic insights that may inform selection of treatment targets and therapies, disease definitions and optimal outcome measures, and novel clinical trial designs. A central goal of the meeting is to support the translation of findings into recommendations for developing future, evidence-based clinical trials for UCPPS that will ultimately improve patient care. Registration Deadline: October 10, 2022; Workshop Dates: October 17 - 18, 2022
Location: Bethesda, MD, USA
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/research-advances-urologic-chronic-pelvic-pain-syndrome
Oct. 11, 2022
LIPIDMAPS Webinar: "Quantitative high-throughput lipidomics - methods, applications and pitfalls"
"Quantitative high-throughput lipidomics - methods, applications and pitfalls"
Presented by: Gerhard Liebisch
Gerhard obtained his PhD at the University of Regensburg. He is a research associate at the Institute of Clinical Chemistry and Laboratory Medicine at the University Hospital of Regensburg and responsible for the instrumental analytics lab (https://lipidomics-regensburg.de/).His research interests focus on the development of mass spectrometric methods for quantification of lipid species. For more than 20 years, these methods have been applied in large-scale clinical studies and basic research including the use of stable isotope labelled lipid(s)/-precursor to trace the transport and metabolism of lipids. He is a co-author of more than 200 papers in peer reviewed international journals, editorial board member of The Journal of Lipid Research.
Webinar Date: October 11th, 2022, 9am PDT | 12pm EDT
Presented by: Gerhard Liebisch
Gerhard obtained his PhD at the University of Regensburg. He is a research associate at the Institute of Clinical Chemistry and Laboratory Medicine at the University Hospital of Regensburg and responsible for the instrumental analytics lab (https://lipidomics-regensburg.de/).His research interests focus on the development of mass spectrometric methods for quantification of lipid species. For more than 20 years, these methods have been applied in large-scale clinical studies and basic research including the use of stable isotope labelled lipid(s)/-precursor to trace the transport and metabolism of lipids. He is a co-author of more than 200 papers in peer reviewed international journals, editorial board member of The Journal of Lipid Research.
Webinar Date: October 11th, 2022, 9am PDT | 12pm EDT
More Information: https://www.lipidmaps.org/resources/webinars/26
Oct. 11, 2022
Poster-Only Abstract Submission Due: Cell Bio 2022
Cell Bio 2022 will return as an in-person meeting December 3-7, 2022, in Washington, DC. We are excited to make it possible for colleagues to reconnect face-to-face, while keeping health and safety paramount. We understand flexibility is also important. In addition to our in-person meeting, limited content will be available on-demand for purchase after the meeting. Poster-Only Submission Deadline: October 11, 2022 by 9 pm EDT
More Information: https://www.ascb.org/cellbio2022/abstracts/
Oct. 12, 2022
NIH Webinar: Meet the GREI Generalist Repositories
Join us for a panel discussion with the 6 generalist repositories participating in the NIH Generalist Repository Ecosystem Initiative (GREI). Learn about common features and capabilities across repositories as well as repositories that support specific use cases. Discover how these repositories are working together to support NIH-funded researchers and participate in an audience Q&A.
Speakers: Sonia Barbosa (Dataverse), Jennifer Gibson (Dryad), Ana Van Gulick (Figshare), Luca Belletti (Mendeley Data), Eric Olson (Open Science Framework), Ida Sim (Vivli)
Introduction by: Ishwar Chandramouliswaran (NIH ODSS)
Webinar Date: October 12, 2022 10:00 PM PT
Other NIH Generalist Repository Ecosystem Initiative (GREI) Webinar Dates: September 15, November 10, & December 8
Speakers: Sonia Barbosa (Dataverse), Jennifer Gibson (Dryad), Ana Van Gulick (Figshare), Luca Belletti (Mendeley Data), Eric Olson (Open Science Framework), Ida Sim (Vivli)
Introduction by: Ishwar Chandramouliswaran (NIH ODSS)
Webinar Date: October 12, 2022 10:00 PM PT
Other NIH Generalist Repository Ecosystem Initiative (GREI) Webinar Dates: September 15, November 10, & December 8
More Information: https://datascience.nih.gov/grei-collaborative-webinar-series
Oct. 14, 2022
Abstract Submission Due: Endocrine Society Meeting "Achieving Higher-Resolution in Neuroendocrinology"
This new half-day meeting is designed for basic scientists at all career stages who are interested in the latest technologies that can be applied to neuroendocrine research. Participants will be able to share research with a focus on innovative techniques and novel approaches of interest to neuroscientists and endocrine scientists. This event, which is free to attend, will feature a symposium with a keynote address followed by a poster session and reception. Abstracts submitted for poster presentations will be considered for one of two short talks.
Meeting Date: November 11, 2022
Abstract Submission Deadline: October 14, 2022
More Information: https://www.endocrine.org/meetings-and-events/sfn-2022
Meeting Date: November 11, 2022
Abstract Submission Deadline: October 14, 2022
More Information: https://www.endocrine.org/meetings-and-events/sfn-2022
Oct. 14, 2022
dkNET Webinar: The Human BioMolecular Atlas Program (HuBMAP)
HuBMAP aims to catalyze the development of an open, global framework for comprehensively mapping the human body at cellular resolution. HuBMAP goals include: (1) Accelerate the development of the next generation of tools and techniques for constructing high resolution spatial tissue maps. (2) Generate foundational 3D tissue atlases. (3) Establish an open data platform. (4) Coordinate and collaborate with other funding agencies, programs, and the biomedical research community. (5) Support projects that demonstrate the value of the resources developed by the program. The HuBMAP Portal can be found at https://portal.hubmapconsortium.org and the Visible Human MOOC describes the compilation and coverage of HuBMAP data, demonstrates new single-cell analysis and mapping techniques, and introduces major features of the HuBMAP portal.
The top 3 key questions that HuBMAP can answer:
1. What assay types are best to map the human body in 3D and across scales?
2. What Common Coordinate System (CCF) is best to construct the Human Reference Atlas?
3. How can others help construct and/or use the Human Reference Atlas?
Presenters:
Katy Börner, PhD, Victor H. Yngve Distinguished Professor of Engineering and Information Science, Department of Intelligent Systems Engineering and Information Science, Indiana University
Jeffrey Spraggins, PhD, Assistant Professor, Department of Cell and Developmental Biology, Vanderbilt University
More Information: https://dknet.org/about/blog/2495
Oct. 17-21, 2022
MMPC Glucose Clamping the Conscious Mouse: A Laboratory Course
The Vanderbilt-NIDDK Mouse Metabolic Phenotyping Center (MMPC) presents the 19th annual course -
Glucose Clamping the Conscious Mouse: A Laboratory Course
A week-long course to familiarize participants with methods, protocols and quantitative tools necessary to perform glucose clamps in the conscious mouse. This course is intended for investigators and staff who wish to make clamping a regular component of their research program.
Registration: This course operates on a rolling waitlist due to the number of surgical spaces available. Please contact mmpc@vanderbilt.edu to be added to the list.
Course Dates: October 17-21, 2022
Glucose Clamping the Conscious Mouse: A Laboratory Course
A week-long course to familiarize participants with methods, protocols and quantitative tools necessary to perform glucose clamps in the conscious mouse. This course is intended for investigators and staff who wish to make clamping a regular component of their research program.
Registration: This course operates on a rolling waitlist due to the number of surgical spaces available. Please contact mmpc@vanderbilt.edu to be added to the list.
Course Dates: October 17-21, 2022
Location: Nashville, TN, USA
More Information: https://www.mmpc.org/shared/courses.aspx
More Information: https://www.mmpc.org/shared/courses.aspx
Oct. 17-18, 2022
NIDDK Workshop: Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies
Urologic Chronic Pelvic Pain Syndrome (UCPPS) represents both Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS). The Research Advances for Urologic Chronic Pelvic Pain Syndrome: Informing the Next Generation of Clinical Studies meeting will provide a forum for exchange of new insights into UCPPS underlying mechanisms and clinical characteristics. The meeting will highlight findings from the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network and other investigators working in the UCPPS field, as well as advances in other areas that may inform these efforts. Major themes will include strategies for identification of phenotypic sub-groups, mechanistic insights that may inform selection of treatment targets and therapies, disease definitions and optimal outcome measures, and novel clinical trial designs. A central goal of the meeting is to support the translation of findings into recommendations for developing future, evidence-based clinical trials for UCPPS that will ultimately improve patient care.
Registration Deadline: October 10, 2022
Workshop Dates: October 17 - 18, 2022
Registration Deadline: October 10, 2022
Workshop Dates: October 17 - 18, 2022
Location: Bethesda, MD, USA
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/research-advances-urologic-chronic-pelvic-pain-syndrome
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/research-advances-urologic-chronic-pelvic-pain-syndrome
Oct. 19, 2022
Abstract Submission Due: CAIRIBU 2022 Annual Meeting
The purpose of the annual CAIRIBU meeting is to bring together the Directors and research teams of the NIDDK U54 O’Brien Urology Centers, the P20 Exploratory Centers for Interdisciplinary Research in Benign Urology, and the Multidisciplinary K12 Urologic Research (KURe) and Urological Epidemiology (KEpi) Institutional Research Career Development Programs. Collectively, these Centers and Programs are part of the CAIRIBU umbrella – Collaborating for the Advancement of Interdisciplinary Research in Benign Urology. The annual meeting allows for the exchange of scientific knowledge about advances in benign genitourinary research and provides a platform for building interactions between CAIRIBU Centers and Programs and between CAIRIBU investigators and the broader benign urologic research community. Primary objectives of the meeting include sharing research resources and advancing students and early investigators in their development as future leaders in the field of benign urology. Interactive poster sessions during the meeting will feature the work of trainees and early-stage investigators whose abstracts are selected for presentation. Meeting Dates: November 30 - December 2, 2022; Registration Deadline: November 29, 2022; Abstract Deadline: October 19, 2022
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/cairibu-2022-annual-meeting
More Information: https://www.niddk.nih.gov/news/meetings-workshops/2022/cairibu-2022-annual-meeting
Oct. 28, 2022
Kidney X Competition Submission Due: Artificial Kidney Prize, Phase 2, Track One
Track One: Accelerating the Prototype Bioartificial Kidney
Track Two: Components and Tools that Enable the Development of an Artificial Kidney
Track One Submission Due: October 28, 2022
Track Two Submission Due: January 28, 2023
More Information: https://www.kidneyx.org/akp
Funding Opportunities Information and Deadlines in October 2022
Oct. 04, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.
Letter of Intent Deadline: 30 days prior to the application due date.
Letter of Intent Deadline: 30 days prior to the application due date.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-034.html
Oct. 05, 2022
NIH Funding Opportunity Application Due: Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Populations with Health Disparities (R01 Clinical Trial Optional)
This initiative will support innovative research to develop, test and evaluate multi-level/multi-component strategies (including models of health care) to effectively adapt and implement comprehensive clinical care for individuals with Type 2 diabetes mellitus from populations with health disparities concordant with recommended and evidence-based guidelines.
Letter of Intent due 30 days prior to application.
More Information: https://grants.nih.gov/grants/guide/pa-files/pa-21-232.html
Letter of Intent due 30 days prior to application.
More Information: https://grants.nih.gov/grants/guide/pa-files/pa-21-232.html
Oct. 05, 2022
NIH Funding Opportunity Application Due: Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the leading edge of the field will change over time and will be updated regularly through the NIH Guide to Grants and Contracts and hyperlinked to this FOA.
More Information: https://grants.nih.gov/grants/guide/pa-files/pas-22-096.html
More Information: https://grants.nih.gov/grants/guide/pa-files/pas-22-096.html
Oct. 05, 2022
NIH Funding Opportunity Application Due: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.
Letter of Intent Deadline: 30 days prior to the application due date
More Information: https://grants.nih.gov/grants/guide/pa-files/par-22-105.html
Letter of Intent Deadline: 30 days prior to the application due date
More Information: https://grants.nih.gov/grants/guide/pa-files/par-22-105.html
Oct. 05, 2022
NIDDK Funding Opportunity First Available Date: Notice of Special Interest (NOSI): Research on the Health of Sexual and Gender Minority (SGM) Populations
This Notice is a reissue of and supersedes NOT-MD-19-001 - Notice of Special Interest in Research on the Health of Sexual and Gender Minority (SGM) Populations which calls for research on the health of sexual and gender minority populations. SGM populations include, but are not limited to, individuals who identify as lesbian, gay, bisexual, asexual, transgender, Two-Spirit, queer, and/or intersex. Individuals with same-sex or -gender attractions or behaviors and those with a difference in sex development are also included. These populations also encompass those who do not self-identify with one of these terms but whose sexual orientation, gender identity or expression, or reproductive development is characterized by non-binary constructs of sexual orientation, gender, and/or sex. Although there has been an increase in SGM-focused health research in recent years, there remains a need for further research on the health of these populations. This Notice encourages research that describes the biological, clinical, behavioral, and social processes that affect the health and development of SGM populations and individuals and their families, and that leads to the development of acceptable and appropriate health interventions and health service delivery methods that will enhance health and development of these populations.
More Information: https://grants.nih.gov/grants/guide/notice-files/not-md-22-012.html
More Information: https://grants.nih.gov/grants/guide/notice-files/not-md-22-012.html
Oct. 05, 2022
NIH Funding Opportunity First Available Date: Notice of Special Interest (NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity
The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes.
It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.
It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.
More Information: https://grants.nih.gov/grants/guide/notice-files/not-md-22-012.html
Oct. 05, 2022
NIDDK Funding Opportunity Application Due: Notice of Special Interest (NOSI): Stimulating Research to Understand and Address Hunger, Food and Nutrition Insecurity
The purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security and the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new measures for nutrition security and assessment of food insecurity that are broadly applicable. . It was developed by the Office of Nutrition Research (ONR) Implementation Working Group on Nutrition and Health Disparities in collaboration with NIH Institutes and Centers (ICs) and Offices in support of the goals and objectives of the Strategic Plan for NIH Nutrition Research.
(NIDDK) Application Deadline: October 5, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/not-od-22-135.html
(NIDDK) Application Deadline: October 5, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/not-od-22-135.html
Oct. 06, 2022
NIH Funding Opportunity Application Due: Regenerative Medicine Innovation Projects (RMIP) Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA) support the Regenerative Medicine Innovation Project (RMIP), which aims to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. Before a research team undertakes a clinical trial, it is critical to have clear delineation and documentation of the trial’s rationale, design, analytic techniques, protocols, and procedures in a Manual of Procedures (MOP). Additionally, there are other elements essential to the launching of a trial, such as obtaining regulatory authorizations or approvals and establishing agreements with requisite partners including cell manufacturing and production facilities, assay or cell analysis centers, and data coordinating centers. These activities are often costly and time-consuming, and they may involve collection of preliminary data to assess feasibility. Applicants may use the RMIP Clinical Trial Planning Grant to support the preparation of a clinical trial MOP and procedures necessary for implementing a clinical trial to evaluate interventions (or new treatments) that explore and enable the evaluation of the safety and/or efficacy of RM interventions using adult stem cells that are not of embryonic or fetal origin.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-020.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-020.html
Oct. 06, 2022
NIH Funding Opportunity Application Due: Regenerative Medicine Innovation Projects (RMIP) Investigator- Initiated Studies (Collaborative U01 – Clinical Trial Not Allowed)
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-019.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-019.html
Oct. 06, 2022
NIH Funding Opportunity Application Due: Regenerative Medicine Innovation Project (RMIP) Investigator-Initiated Clinical Trials (UG3/UH3 – Clinical Trial Required)
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration (FDA), seek highly meritorious clinical trial applications proposing to explore and enable the development of safe and effective regenerative medicine (RM) interventions using adult stem cells. This Funding Opportunity Announcement (FOA), issued as part of the Regenerative Medicine Innovation Project (RMIP), represents one step in fulfilling a statutory provision set forth in the 21st Century Cures Act. Applications submitted in response to this bi-phasic, milestone-driven cooperative agreement FOA are expected to propose highly innovative projects with a focus on solutions to widely-recognized issues in the development of safe and effective RM therapies. Of particular interest are projects using RM products that have undergone appropriate product development and pre-clinical studies and have demonstrated readiness to advance into clinical trials. This FOA seeks Phase I and beyond clinical trial applications that present a strong scientific rationale for the proposed clinical trial and a comprehensive scientific and operational plan. Trials must be relevant to the research mission of one or more participating NIH Institutes and Centers and meet the NIH definition of a clinical trial (see NOT-OD-15-015). Applications will be required to include plans for project management, participant recruitment and retention, performance milestones, conduct of the trial, and dissemination of results.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-017.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-hl-23-017.html
Oct. 07, 2022
NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-011.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-011.html
Oct. 07, 2022
NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-012.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-012.html
Oct. 07, 2022
NIH Funding Opportunity Letter of Intent Due: Platform Clinical Trials of Genome Editors in Multiple Diseases (UG3/UH3, Clinical Trial Required)
The purpose of this FOA is to provide support for applications that propose a novel genome editing clinical trial that includes at least two different diseases, using the same genome editor, route of administration, and delivery system. Letter of Intent Deadline: October 7, 2022; Application Deadline: November 10, 2022.
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-22-016.html
Oct. 07, 2022
NIDDK Funding Opportunity Application Due: Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-021.html
Oct. 09, 2022
NIDDK Funding Opportunity Letter of Intent Due: NIDDK Research Education Program Utilizing Stimulating Peripheral Activity to Relieve Conditions (SPARC) - Generated Resources (R25 Clinical Trial Not Allowed) Letter of Intent Due Date
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Research Experiences; Courses for Skills Development. This Funding Opportunity Announcement (FOA) invites applications to establish research programs for qualified graduate students, post-doctoral fellows, medicalresidents, biomedical engineers, and clinical fellows to engage in neuroscience research experiences relevant to the mission of NIDDK and its partnership with the Common Fund program, Stimulating Peripheral Activity to Relieve Conditions (SPARC). The intent is to leverage this partnership to provide resources for short-term research experiences that would necessarily use SPARC-generated resources (datasets/maps/models) as the foundation for the research experience in conjunction with educational activities that may be combined with hands-on computational or ‘wet lab’ projects. The goal is that the research experiences will be impactful and ideally develop new skills and produce new knowledge that could sustain future NIDDK-funded research careers. Letter of Intent Deadline: October 9, 2022. Application Deadline: November 9, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-20-020.html
Oct. 10, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Interdisciplinary Team Science to Uncover the Mechanisms of Pain Relief by Medical Devices (RM1 Clinical Trial Optional)
This funding opportunity announcement (FOA) is designed to support interdisciplinary research teams of multiple PDs/PIs to investigate the mechanism of action of pain relief by medical devices with the overall goal of optimizing therapeutic outcomes for FDA-approved or -cleared technologies. Teams must leverage appropriate multi-disciplinary expertise to develop new principles and methods for experimentation, analysis, and interpretation. Teams are encouraged to consider objectives that will produce major advances in the understanding of pain relief by medical devices.
Letter of Intent Deadline: 30 days prior to the application due date. Application Deadline(s): October 10, 2022 ; June 13, 2023 (...)
Letter of Intent Deadline: 30 days prior to the application due date. Application Deadline(s): October 10, 2022 ; June 13, 2023 (...)
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-23-003.html
Oct. 11, 2022
NIH Funding Opportunity Application Due: HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)
The purpose of this funding opportunity announcement is to support research that uses human tissue or cells to generate comprehensive datasets for the discovery and characterization of functional genetic elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain transduction, transmission, and processing. This FOA will support concerted multidisciplinary team science efforts that apply large-scale high-throughput approaches on tissues involved in human pain processing as part of the NIH HEAL Initiative’s Program to Reveal and Evaluate Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISION Human Pain). U19 Centers will operate as a cooperative network to promote collaboration and coordination of research activities. U19 Centers will also coordinate with the U24 HEAL Initiative: Human Pain-associated Genes & Cells Data Coordination and Integration Center that will curate, harmonize, and integrate datasets generated by this U19 research program.
Letter of Intent Deadline: 30 days prior to the application due date. Application Deadline(s): October 11, 2022 ; March 09, 2023
Letter of Intent Deadline: 30 days prior to the application due date. Application Deadline(s): October 11, 2022 ; March 09, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-ns-22-018.html
Oct. 14, 2022
NIDDK Funding Opportunity Letter of Intent Due: Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)
The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later stage therapeutics development and preclinical efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to diabetes and other endocrine and metabolic diseases, liver and other digestive diseases, nutritional disorders, obesity, kidney and urological diseases, and hematologic diseases. Additional information concerning programmatic areas at NIDDK is available at www.niddk.nih.gov/research-funding/research-programs and applicants are strongly encouraged to discuss research priorities with the Scientific Contacts for each division.
The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, identifying new therapeutic uses for existing compounds, or identifying mechanism of action for therapeutic leads. Letter of Intent Deadline: October 14, 2022, (...); Application Deadline: November 14, 2022, (...)
The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, identifying new therapeutic uses for existing compounds, or identifying mechanism of action for therapeutic leads. Letter of Intent Deadline: October 14, 2022, (...); Application Deadline: November 14, 2022, (...)
More Information: https://grants.nih.gov/grants/guide/pa-files/par-22-111.html
Oct. 17, 2022
NIDDK Funding Opportunity Letter of Intent Due: Type 1 Diabetes Mellitus Stakeholder Engagement Innovation Center to Advance Health Equity (U2C Clinical Trial Not Allowed)
This U2C funding opportunity announcement (FOA) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) initiative to establish a novel national Stakeholder Engagement Innovation Center for advancing equity in type 1 diabetes research (SEIC-T1D). A primary goal of the SEIC-T1D is to accelerate equitable engagement of diverse stakeholders (specifically people from NIH designated health disparities populations) in T1D research; particularly those from communities that experience diabetes-related health disparities and live within the healthcare and social systems that negatively impact community members’ and patients’ health. The SEIC-T1D will provide highly specialized research resources to support investigators by fully embedding communities, people living with T1D, and other stakeholders into the full spectrum of research activities through expert consultations and education in principles and methods of community-engaged research. The SEIC-T1D will also establish a network consisting of diverse, multidisciplinary research investigators with expertise in T1D and community-engaged methods, community experts with lived experiences, and representatives of various health and other organizations deemed essential for addressing disparities and advancing health equity in T1D early detection and treatment. Letter of Intent Deadline: October 17, 2022; Application Deadline: November 17, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-019.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-019.html
Oct. 17, 2022
NIH Funding Opportunity Letter of Intent Due: Interventions that Address Structural Racism to Reduce Kidney Health Disparities – Research Coordinating Center (U24 - Clinical Trial Not Allowed)
The Interventions that Address Structural Racism to Reduce Kidney Health Disparities Consortium aims to foster community-engaged intervention research to address structural racism to reduce health disparities among individuals living with kidney disease. The Consortium will consist of one Research Coordinating Center and multiple Intervention Sites (see RFA-DK-22-014) that will work collaboratively to develop, implement and evaluate meaningful interventions that aim to dismantle or mitigate the effects of structural racism to reduce kidney health disparities. This Funding Opportunity Announcement (FOA) invites applications for the Research Coordinating Center (RCC) that will lead, manage, and harmonize efforts for the Consortium. The specific activities of the RCC will include: 1) providing organization, management, and administrative support of Consortium activities; 2) providing research coordination, data management and data analyses for Consortium studies; and 3) fostering research collaborations and helping to build a community of investigators with skills to develop, implement, and disseminate effective, scalable, and sustainable interventions that address the structural drivers of kidney health disparities. Letter of Intent Deadline: October 17, 2022; Application Deadline: November 17, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-015.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-015.html
Oct. 17, 2022
NIH Funding Opportunity Letter of Intent Due: Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required)
The Interventions that Address Structural Racism to Reduce Kidney Health Disparities Consortium aims to foster community-engaged intervention research to address structural racism to reduce health disparities among individuals living with kidney disease.This Funding Opportunity Announcement (FOA) invites applications for Intervention Sites that will work collaboratively with a Research Coordinating Center (RCC) (see RFA-DK-22-015) to develop and test meaningful interventions that aim to dismantle or mitigate the effects of structural racism to reduce kidney health disparities. Studies proposed by the successful applicants may be substantially revised prior to being undertaken by the Consortium, including the potential of harmonizing intervention components and data collection measures across Intervention Sites.Letter of Intent Deadline: October 17, 2022; Application Deadline: November 17, 2022.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-014.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-014.html
Oct. 18, 2022
NIH Funding Opportunity First Available Date: HEAL Initiative Notice of Special Interest (NOSI): Development and Validation of Pain-Related Models and Endpoints to Facilitate Non-Addictive Analgesic Discovery
The purpose of this Notice of Special Interest (NOSI) is to encourage the development, validation, and replication of animal models that recapitulate the phenotypic and physiologic characteristics of a defined pain type/indication and/or disease-associated pain condition and endpoints or outcome measures that can be used therein. The goal of this NOSI is to improve the translational application of animal models and/or outcome measures for the development of non-addictive analgesics. Ideally, models or measures proposed for this NOSI would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This NOSI is not specific for any one or group of pain conditions. Projects focused on acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, obstetric pain, gynecologic pain, post stroke pain, myofascial pain, painful disorders of the orofacial region, pain co-occuring with substance use disorders, and other conditions will be considered. In addition to replication and validation of more commonly used translational animal models of pain, the development of animal models of pain for understudied pain conditions, age groups or less developed models is also encouraged.
More Information: https://grants.nih.gov/grants/guide/notice-files/not-ns-22-095.html
More Information: https://grants.nih.gov/grants/guide/notice-files/not-ns-22-095.html
Oct. 20, 2022
NIH Funding Opportunity Application Due: Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions (R01 Clinical Trial Not Allowed)
The purpose of the Funding Opportunity Announcement is to invite applications to identify and characterize microbial metabolites that will establish causal associations between microbial metabolism and host health and disease. Data acquired through this initiative will be used to create a knowledgebase of microbial metabolites and associated functions that will be provided to the research community. Development of the database and knowledge portal for these awards will be supported under a separate initiative: RFA-DK-21-014, Identification and Characterization of Bioactive Microbial Metabolites for Advancing Research on Microbe-Diet-Host Interactions Knowledgebase Management Center (Clinical Trial Not Allowed).
Application Deadline: October 20, 2022; June 22, 2023; October 19, 2023
More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html
Application Deadline: October 20, 2022; June 22, 2023; October 19, 2023
More Information: https://grants.nih.gov/grants/guide/pa-files/par-21-253.html
Oct. 26, 2022
NIDDK Funding Opportunity Application Due: Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed)
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-001.html
Oct. 26, 2022
NIDDK Funding Opportunity Application Due: Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-009.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-22-009.html
Oct. 26, 2022
NIDDK Funding Opportunity Application Due: Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through controlled manipulation of beta cell replication or islet cell plasticity, reprogramming of non-beta cells into beta-like cells, or shielding of residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-009.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-009.html
Oct. 26, 2022
NIDDK Funding Opportunity Application Due: Mass Spectrometric Assays for the Reliable and Reproducible Detection of Proteins/Peptides of Importance in Type 1 Diabetes (T1D) Research (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-031.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-21-031.html
Oct. 27, 2022
NIDDK Funding Opportunity Application Due: Multidisciplinary K12 Urologic Research (KURe) Career Development Program (K12 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications to support institutional career development programs in urological research that will assist individuals with doctorate degrees (either clinical or professional) with an interest in benign urological disease or urological research to develop the skills necessary to initiate and sustain an independent research career in urological research. Research areas supported by this initiative must be related to the mission of the NIDDK (https://www.niddk.nih.gov/research-funding/research-programs#urologic-diseases). This Funding Opportunity Announcement (FOA) allows appointment of Scholars (K12) proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-006.html
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-006.html
Oct. 27, 2022
NIDDK Funding Opportunity Application Due: Promoting Organ and Tissue Donation Among Health Disparity Populations (R01 - Clinical Trial Optional)
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-003.html
Oct. 27, 2022
NIDDK Funding Opportunity Application Due: NIDDK Central Repository Non-renewable Sample Access (X01 Clinical Trial Not Allowed)
More Information: https://grants.nih.gov/grants/guide/pa-files/par-22-171.html
Oct. 30, 2022
NIDDK Funding Opportunity Letter of Intent Due: Helping to Accelerate Research Potential (HARP) (UE5 - Clinical Trial Not Allowed)
The NIH Research Education Cooperative Agreements Program (UE5) supports research education activities in the mission areas of the NIH. The overarching goal of this Helping to Accelerate Research Potential (HARP) UE5 program is to complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. The main objective of the HARP UE5 program is to provide opportunities and mentorship for current NIDDK grantees, especially postdoctoral scholars and junior faculty from diverse backgrounds, to enhance their skills in areas that are critical for establishing and maintaining successful independent academic research careers. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on:
Courses for Skills Development
Mentoring Activities
The HARP UE5 program aims to develop a network of mentors and scholars, with the expectation that scholars will apply for a career stage-appropriate NIH research project grant (e.g., R01 or R01-equivalent grant for junior faculty scholars; K grant for postdoctoral scholars) after their participation in the program. The scholars of the HARP UE5 program will be assigned by NIDDK staff and UE5 recipients will not be responsible for the recruitment of scholars.
Letter of Intent Deadline: October 30, 2022
Application Deadline: November 30, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-002.html
Courses for Skills Development
Mentoring Activities
The HARP UE5 program aims to develop a network of mentors and scholars, with the expectation that scholars will apply for a career stage-appropriate NIH research project grant (e.g., R01 or R01-equivalent grant for junior faculty scholars; K grant for postdoctoral scholars) after their participation in the program. The scholars of the HARP UE5 program will be assigned by NIDDK staff and UE5 recipients will not be responsible for the recruitment of scholars.
Letter of Intent Deadline: October 30, 2022
Application Deadline: November 30, 2022
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-002.html
Oct. 31, 2022
NIH Funding Opportunity Application Due: Notice of Intent to Publish a Funding Opportunity Announcement for Advanced Training in Artificial Intelligence for Precision Nutrition Science Research (AIPrN) – Institutional Research Training Programs (T32)
The National Institutes of Health (NIH) Office of Nutrition Research (ONR) and participating NIH Institutes and Centers (ICs) intend to publish a Funding Opportunity Announcement (FOA) for new applications that will support new institutional research training programs (predoctoral, postdoctoral or both) in artificial intelligence (AI) for precision nutrition (AIPrN) that will focus on integration of the domains of precision nutrition, AI including machine learning (ML), systems biology, systems science, “Big Data”, and computational analytics. The goal is to build a future workforce that will be able to use growing data resources to tackle complex biomedical challenges in nutrition science that are beyond human intuition. It is hoped such research will lead to the development of innovative solutions to combat diet-related chronic diseases within the mission areas of the participating ICs.
First Estimated Application Deadline: October 31, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-168.html
First Estimated Application Deadline: October 31, 2022
More Information: https://grants.nih.gov/grants/guide/notice-files/NOT-OD-22-168.html
About
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant 2U24DK097771-09.
Recent News Entries
Contact Us
Email: info_at_ dknet.org
Stay Connected
X